【ChiCTR1900025550】Concurrent Transcranial Direct Current Stimulation with Cognitive Training for Cognitive Functions of Schizophrenia Patients
ChiCTR1900025550
正在进行
/
/
/
2019-08-31
/
/
精神分裂症
Concurrent Transcranial Direct Current Stimulation with Cognitive Training for Cognitive Functions of Schizophrenia Patients
A Randomised Controlled Trial of Online Transcranial Direct Current Stimulation (tDCS) in Enhancing the Effects of Cognitive Training in patients with Schizophrenia
The primary objective of the study is to investigate the adjunct effect of online tDCS with cognitive training on specific cognitive domains in stable schizophrenia patients. (i) right after the intervention (ii) whether maintenance effect at 1 month after intervention. The secondary objective of the study is to probe (i) any effects on affective , psychotic and negative symptoms; (ii) psychosocial functioning, subjective quality of life (QOL); (iii) the motivation and enjoyment of continuing playing the computerized cognitive training; (iv) the tolerability and adverse events of tDCS among patients with schizophrenia.
随机平行对照
治疗新技术
The subjects will be randomly allocated to the intervention group or the control group by a block randomization procedure (1:1 allocation) . The randomization sequence will be generated by an online randomization tool (www.sealedenvelop.com) .
Double Blind
N/A
/
16
/
2019-08-01
2020-06-30
/
1. Patients receiving rehabilitation service in Tai Po Hospital aged between 18-65 years old; 2. diagnosis of schizophrenia meeting the diagnostic criteria of the World Health Organizations 10thversion of the International Statistical Classification of Disease and Related Health Problems (ICD-10),it will be made clinically by the study psychiatrist based on ICD-10; 3. right-handedness; 4. able to understand spoken instructions in Cantonese and able to read traditional Chinese.；
请登录查看1. History of significant head trauma; 2. active abuse of alcohol or illegal substances; 3. significant neurologic history such as dementia, stroke, seizure, Parkinsons disease, multiple sclerosis; 4. concurrent use of cognitive-enhancing medications e.g. acetylcholinesterase inhibitors ; 5. documented history of learning disability; f. implanted with pacemakers, intracranial electrodes, defibrillators; g. changes in medication regime over the 2 weeks before or during the study period.；
请登录查看香港中文大學大埔醫院
/
香港中文大學大埔醫院的其他临床试验
香港中文大學大埔醫院的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04